







Newly Reported Substances: The following substances were reported to NFLIS-Drug for the first time between July 1, 2023, and September 30, 2023.




West




Midwest

N-Desethyl etonitazene




South


NMDMSB



CHO-4'-Me-5'-Br-FUBOXPYRA




Northeast



South and Northeast

Ethyleneoxynitazene



Snapshot of Drug Reports Received by NFLIS-Drug

The tables on the right present the top drug reports in each category received by NFLIS-Drug between July 1, 2023, and September 30, 2023.

Top 5 Reported Drugs	187,502
Methamphetamine	77,345
Fentanyl	38,078
Cocaine	37,766
Cannabis/THC	27,473
Heroin	6,840





Psychedelics	3,481
Psilocin	1,849
Psilocin/psilocybin	760
Lysergic acid diethylamide (LSD)	462
Psilocybin	410

Selected Benzimidazole Opioids	355
Metonitazene	213
Protonitazene	118
Isotonitazene	9
N-Pyrrolidino etonitazene	9
Ethyleneoxynitazene	6

Steroids	278
Testosterone	166
Trenbolone	42
Oxandrolone	25
Methandrostenolone	23
Nandrolone	22

Fentanyl-Related Compounds	9,150
4-ANPP	4,643
Fluorofentanyl	3,267
Fluorofentanyl (unspecified)	1,975
para-Fluorofentanyl	1,289
meta-Fluorofentanyl	3
Acetyl fentanyl	817
Phenethyl 4-ANPP	337
Ethyl 4-ANPP	86

Upward Trends, by Date Submitted to Laboratory



Data Disclaimer: Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in October 2023. Data in the Newly Reported Substances and Snapshot of Drug Reports Received by NFLIS-Drug sections include only drugs submitted to laboratories on or after July 1, 2022. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.dea/diversion.usdoj.gov/nflisdata/docs/2k17NFLISQA.pdf>. NFLIS reports are available at <https://www.nflis.dea/diversion.usdoj.gov/publicationsRedesign.xhtml>. Send questions and comments to NFLIS@dea.gov.

